Mylan launches generic Avodart capsules in US
Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
The RAC also issued recommendations on several design elements of the research and clinical development program. DTX301 is an adeno-associated virus (AAV) gene therapy product being developed to